期刊文献+

局部进展期前列腺癌的治疗进展 被引量:3

Therapeutic progress of locally advanced prostate cancer
原文传递
导出
摘要 局部进展性前列腺癌患者的标准治疗模式目前处于争议当中。随着诊疗技术的进步,外科治疗、放疗、内分泌治疗等治疗模式近年均取得不同进展,在肿瘤控制率、生存期上各有千秋,同时并发症、对生活质量的影响亦不同。 The standard treatment mode of locally advanced prostate cancer is still controversial. With the progress of medical technology, treatments of prostate cancer achieve different progresses in surgical treat- ment, radiotherapy and endocrine therapy. The three treatment modes have diverse tumor growth control rate and survival period, which have different complications and different influences on the quality of life.
出处 《国际肿瘤学杂志》 CAS 2013年第3期225-228,共4页 Journal of International Oncology
基金 基金项目:国家自然科学基金(30973438、81001002)
关键词 前列腺肿瘤 治疗 预后 Prostatic neoplasms Treatment Prognosis
  • 相关文献

参考文献30

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin, 2010, 60(5) :277-300.
  • 2陈万青,张思维,郑荣寿,雷正龙,李光琳,邹小农,赵平.中国肿瘤登记地区2007年肿瘤发病和死亡分析[J].中国肿瘤,2011,20(3):162-169. 被引量:329
  • 3Berglund A, Garmo H, Robinson D, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer,2012, 48( 1 ) :75-84.
  • 4Gomella LG, Lin J, Hoffman-Censits J, et al. Enhancing prostate cancer care through the muhidisciplinary clinic approach: a 15-year experience. J Oncol Pract,2010,6(6) :e8-10.
  • 5Tanaka N, Fujimoto K, Hirayama,et al. Trends of the primary thera- py for patients with prostate cancer in Nara uro-oncological research group (NUORG) : a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncoi,2010,40(6) :588-592.
  • 6Lee HW, Seo SI, Jeon SS, et al. Can we predict real 33 stage pros- tate cancer in patients with clinical q3 ( cT3 ) disease before radical prostatectomy?. Yonsei Med J, 2010, 51(5) :700-707.
  • 7Jonian S, Hsu CY, Gontero P, et al. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. Scand J Urol Nephrol, 2012, 46(3) :164-171.
  • 8Milonas D, Smailyte G, Jievaltas M. Oncologic outcomes of surgery in T3 prostate cancer: experience of a single tertiary center. Adv Urol, 2012, 2012 : 164263.
  • 9Hsu CY, Wildhagen MF, Van Poppel H, et al. Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatec- tomy. BJU Int, 2010, 105( 11 ) :1536-1540.
  • 10Walz J, Joniau S, Chun FK, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int, 2011, 107 (5) :765-770.

二级参考文献10

  • 1Bray F, Parkin DM, Evaluation of data quality in the cancer registry: Principles and methods. Part I : Comparability, validity and timeliness [J]. Eur J Cancer, 2009, 45(5): 747-755.
  • 2Curado MP, Edwards B, Shin HR et al. Cancer incidence in five conti- nents, Vol. IX. IARC scientific publications No. 160[M]. Lyon: IARC, 2007.
  • 3Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IAtlC technical report No.19[M]. Lyon: IARC. 1994.
  • 4Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC technical report No.42[M]. Lyon: IARC, 2005.
  • 5Felay J. The IARCcrgTools program [CP/OL]. http://www.iaer.com.fr/iarc- crgtools.htm, 2006.
  • 6全国肿瘤登记中心.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2004.48-50.
  • 7陈万青,张思维.中国肿瘤登记的代表性研究[J].中国肿瘤,2008,17(10):832-835. 被引量:12
  • 8陈万青,赵平,饶克勤,孔灵芝,胡建平.健全我国肿瘤登记系统[J].中华预防医学杂志,2010,44(5):374-375. 被引量:12
  • 9张思维,雷正龙,李光琳,邹小农,赵平,陈万青.中国肿瘤登记地区2006年肿瘤发病和死亡资料分析[J].中国肿瘤,2010,19(6):356-365. 被引量:192
  • 10陈建国.癌症登记资料的质量评价[J].中国肿瘤,1999,8(3):100-104. 被引量:38

共引文献328

同被引文献31

  • 1杨艳,陈莉.前列腺癌患者去势治疗后心理障碍的原因分析及干预策略[J].上海交通大学学报(医学版),2011,31(6):730-732. 被引量:14
  • 2陈伟,王国民.雄激素阻断治疗后前列腺癌组织中肿瘤干细胞比例变化[J].肿瘤防治研究,2014,41(2):128-130. 被引量:3
  • 3Mitsiades N.A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer[J].Cancer Res,2013,73(15):4599-4605.
  • 4Mottet N,Van Damme J,Loulidi S,et al.Intermittent hormonal therapy in the treatment of metastatic prostate cancer:a randomized trial[J].BJU Int,2012,110(9):1262-1269.
  • 5Ryan CJ,Molina A,Li J,et al.Serum androgens as prognostic biomarkers in castration-resistant prostate cancer:results from an analysis of a randomized phase III trial[J].J Clin Oncol,2013,31(22):2791-2798.
  • 6Lunardi A,Ala U,Epping MT,et al.A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer[J].Nat Genet,2013,45(7):747-755.
  • 7Heidenreich A,Bastian PJ,Bellmunt J,et al.EAU guidelines on prostate cancer.Part II:Treatment of advanced,relapsing,and castration-resistant prostate cancer[J].Eur Urol,2014,65(2):467-479.
  • 8Sciarra A,Abrahamsson PA,Brausi M,et al.Intermittent androgen-deprivation therapy in prostate cancer:a critical review focused on phase 3 trials[J].Eur Urol,2013,64(5):722-730.
  • 9王潇然,王伟华.激素非依赖性前列腺癌的治疗进展[J].中国老年学杂志,2011,31(5):903-906. 被引量:1
  • 10唐翌姝,张叔人.前列腺癌免疫治疗进展[J].中华微生物学和免疫学杂志,2011,31(3):283-288. 被引量:1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部